HDAC11, an emerging therapeutic target for metabolic disorders
Histone deacetylase 11 (HDAC11) is the only member of the class IV HDAC, and the latest member identified. It is highly expressed in brain, heart, kidney and some other organs, and located in mitochondria, cytoplasm and nuclei, depending on the tissue and cell types. Although studies in HDAC11 total...
Main Authors: | Huizhen Chen, Chunguang Xie, Qiu Chen, Shougang Zhuang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.989305/full |
Similar Items
-
The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01) -
Critical Functions of Histone Deacetylases (HDACs) in Modulating Inflammation Associated with Cardiovascular Diseases
by: Supaporn Kulthinee, et al.
Published: (2022-08-01) -
The Role of Semaphorins in Metabolic Disorders
by: Qiongyu Lu, et al.
Published: (2020-08-01) -
Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
by: Elizabeth A. Thomas
Published: (2014-05-01) -
Pharmacological and Genetic Inhibition of HDAC4 Alleviates Renal Injury and Fibrosis in Mice
by: Fengchen Shen, et al.
Published: (2022-06-01)